日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial

伊布替尼联合利妥昔单抗对比免疫化疗治疗既往未接受治疗的套细胞淋巴瘤患者（ENRICH）：一项随机、开放标签、2/3期优效性试验

期刊:Lancet
影响因子:88.5
doi:10.1016/S0140-6736(25)01432-1
Lewis, David J; Jerkeman, Mats; Sorrell, Lexy; Wright, David; Glimelius, Ingrid; Poulsen, Christian B; Pasanen, Annika; Rawstron, Andrew; Wader, Karin F; Morley, Nick; Burton, Catherine; Davies, Andrew J; Lagerlöf, Ingemar; Dalal, Surita; De Tute, Ruth; McNamara, Chris; Crosbie, Nicola; Toldbod, Helle Erbs; Sanders, Jeanette; Allgar, Victoria; Aroori, Sree; Warner, Mark; Scully, Claire; Wainman, Brian; Christensen, Jacob Haaber; Riise, Jon; Sonnevi, Kristina; Bishton, Mark J; Eyre, Toby A; Rule, Simon
细胞生物学
淋巴瘤
免疫/内分泌
发表日期：2025
文献求助 收藏

Ibrutinib, lenalidomide, and rituximab in relapsed mantle cell lymphoma: Long-term follow-up of the Nordic Lymphoma Group MCL6 Philemon trial

伊布替尼、来那度胺和利妥昔单抗治疗复发性套细胞淋巴瘤：北欧淋巴瘤组 MCL6 Philemon 试验的长期随访

期刊:Hemasphere
影响因子:14.6
doi:10.1002/hem3.70101
Forsgren, Elin; Jørgensen, Rasmus R K; Bentzen, Hans; Riise, Jon; Haaber, Jacob; Pasanen, Annika; Kuitunen, Hanne; Wader, Karin F; El-Galaly, Tarec C; Hutchings, Martin; Glimelius, Ingrid; Jerkeman, Mats
细胞生物学
淋巴瘤
发表日期：2025
文献求助 收藏

Circulating tumor DNA determinants of response and outcome in relapsed/refractory mantle cell lymphoma

循环肿瘤DNA在复发/难治性套细胞淋巴瘤的治疗反应和预后中的决定因素

期刊:Blood Advances
影响因子:7.1
doi:10.1182/bloodadvances.2025015791
Meriranta, Leo; Rask Kragh Jørgensen, Rasmus; Pasanen, Annika; Kolstad, Arne; Hutchings, Martin; Niemann, Carsten Utoft; El-Galaly, Tarec Christoffer; Riise, Jon; Christensen, Jacob Haaber; Sonnevi, Kristina; Pedersen, Lone Bredo; Wader, Karin Fahl; Glimelius, Ingrid; Leppä, Sirpa; Jerkeman, Mats
细胞生物学
肿瘤
淋巴瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial

在套细胞淋巴瘤中采用维奈托克-R2进行微小残留病灶（MRD）驱动治疗：北欧淋巴瘤组MCL7 VALERIA试验

期刊:Blood Advances
影响因子:7.1
doi:10.1182/bloodadvances.2023011920
Jerkeman, Mats; Kolstad, Arne; Hutchings, Martin; Pasanen, Annika; Meriranta, Leo; Niemann, Carsten Utoft; Kragh Jørgensen, Rasmus Rask; El-Galaly, Tarec Christoffer; Riise, Jon; Leppä, Sirpa; Christensen, Jacob Haaber; Sonnevi, Kristina; Pedersen, Lone Bredo; Wader, Karin Fahl; Glimelius, Ingrid
细胞生物学
淋巴瘤
发表日期：2024
文献求助 收藏

Rituximab-treated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccination

接受利妥昔单抗治疗的淋巴瘤患者在接种新冠疫苗后会产生强烈的 CD8 T 细胞反应。

期刊:British Journal of Haematology
影响因子:3.8
doi:10.1111/bjh.18149
Riise, Jon; Meyer, Saskia; Blaas, Isaac; Chopra, Adity; Tran, Trung T; Delic-Sarac, Marina; Hestdalen, Malu Lian; Brodin, Ellen; Rustad, Even Holth; Dai, Ke-Zheng; Vaage, John Torgils; Nissen-Meyer, Lise Sofie Haug; Sund, Fredrik; Wader, Karin F; Bjornevik, Anne T; Meyer, Peter A; Nygaard, Gro O; König, Marton; Smeland, Sigbjørn; Lund-Johansen, Fridtjof; Olweus, Johanna; Kolstad, Arne
新冠
T细胞
淋巴瘤
CD8
微生物学
细胞生物学
发表日期：2022
文献求助 收藏

BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis

早期多发性骨髓瘤中的 BRAF V600E 突变：对广谱药物反应良好且与预后无关

期刊:Blood Cancer Journal
影响因子:12.9
doi:10.1038/bcj.2015.24
E H Rustad, H Y Dai, H Hov, E Coward, V Beisvag, O Myklebost, E Hovig, S Nakken, D Vodák, L A Meza-Zepeda, A K Sandvik, K F Wader, K Misund, A Sundan, H Aarset, A Waage2
肿瘤
骨髓瘤
发表日期：2015
文献求助 收藏

Activin A inhibits BMP-signaling by binding ACVR2A and ACVR2B

激活素 A 通过结合 ACVR2A 和 ACVR2B 抑制 BMP 信号传导

期刊:Cell Communication and Signaling
影响因子:8.2
doi:10.1186/s12964-015-0104-z
Oddrun Elise Olsen, Karin Fahl Wader, Hanne Hella, Anne Kærsgaard Mylin, Ingemar Turesson, Ingerid Nesthus, Anders Waage, Anders Sundan, Toril Holien
信号转导
发表日期：2015
文献求助 收藏

Case report: A rare case of eccrine carcinoma

病例报告：一例罕见的汗腺癌病例

期刊:International Journal of Surgery Case Reports
影响因子:0.7
doi:10.1016/j.ijscr.2015.08.038
Kshirsagar, Ashok Y; Wader, J V; Nagur, Basavaraj; Biradar, Sangeeta; Savsaviya, Jigneshkumar; Chotai, Trishant; Agarwal, Aman
肿瘤
肿瘤免疫
发表日期：2015
文献求助 收藏

Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin

骨形态发生蛋白 9 通过 ALK2 发出信号来抑制骨髓瘤细胞的生长，但受到内皮因子的抑制

期刊:Blood Cancer Journal
影响因子:12.9
doi:10.1038/bcj.2014.16
O E Olsen, K F Wader, K Misund, T K Våtsveen, T B Rø, A K Mylin, I Turesson, B F Størdal, S H Moen, T Standal, A Waage, A Sundan, T Holien
信号转导
肿瘤
骨髓瘤
肿瘤细胞
发表日期：2014
文献求助 收藏

Primary adenosquamous carcinoma of ampulla of Vater-A rare case report

Vater壶腹原发性腺鳞癌——一例罕见病例报告

期刊:International Journal of Surgery Case Reports
影响因子:0.7
doi:10.1016/j.ijscr.2014.04.009
Kshirsagar, Ashok Y; Nangare, Nitin R; Vekariya, Mayank A; Gupta, Vaibhav; Pednekar, Akshay S; Wader, J V; Mahna, Abhishek
肿瘤
肿瘤免疫
免疫/内分泌
发表日期：2014
文献求助 收藏